Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

To evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta-analysis was conducted. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched from 1950 to October 2013....

Full description

Saved in:

Bibliographic Details
Main Authors:	Feng Sun, Sanbao Chai, Lishi Li, Kai Yu, Zhirong Yang, Shanshan Wu, Yuan Zhang, Linong Ji, Siyan Zhan
Format:	Article
Language:	English
Published:	Wiley 2015-01-01
Series:	Journal of Diabetes Research
Online Access:	http://dx.doi.org/10.1155/2015/157201
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
by: Michael J. DiStefano, et al.
Published: (2025-12-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
by: Noritaka Sawada, et al.
Published: (2020-01-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
by: Luis Alberto Vigara, et al.
Published: (2024-11-01)

Glucagon‐Like Peptide‐1 Receptor Agonists and Anesthesia—Are We Clearer on the Correct Approach?
by: Zachary Bloomgarden
Published: (2024-12-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Perioperative glucagon-like peptide-1 receptor agonists–induced gastroparesis – Is gastric ultrasound the answer?
by: Suryakumar Narayanasamy, et al.
Published: (2024-09-01)

Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
by: Anastasia Shchendrygina, et al.
Published: (2024-09-01)

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
by: Ortal Resnick, et al.
Published: (2025-01-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Quality Assessment of Medical Institutions’ Websites Regarding Prescription Drug Misuse of Glucagon-Like Peptide-1 Receptor Agonists by Off-Label Use for Weight Loss: Website Evaluation Study
by: Rie Oyama, et al.
Published: (2025-01-01)

Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis
by: Muhammed Shabil, et al.
Published: (2024-11-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024-11-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Comparing Glucagon‐like peptide‐1 receptor agonists versus metformin in drug‐naive patients: A nationwide cohort study
by: Kathrine Kold Sørensen, et al.
Published: (2024-10-01)

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
by: Mijin Kim, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence
by: Natalia Gniaź, et al.
Published: (2024-12-01)

Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
by: Mukul Singhal, et al.
Published: (2019-05-01)

Ozempic (Glucagon-like peptide 1 receptor agonist) in social media posts: Unveiling user perspectives through Reddit topic modeling
by: Seraphina Fong, et al.
Published: (2024-12-01)

Long-Acting Glucagon-Like Peptide-1 Receptor Agonist-Induced Rheumatoid Arthritis in a Patient with Type 2 Diabetes Mellitus
by: Koji Kikkawa, et al.
Published: (2021-09-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review
by: Serene Lee, et al.
Published: (2024-11-01)

Impact of Fasting on Physical Activity Motivation and Weight Reduction in Patients Administered Glucagon-Like Peptide-1 Agonists: A Qualitative Study
by: Almaqhawi A, et al.
Published: (2025-01-01)

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
by: Hayeon Kim, et al.
Published: (2024-10-01)

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
by: Tian-Yi Ren, et al.
Published: (2024-10-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes
by: Kevin Y. Heo, BS, et al.
Published: (2024-12-01)

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
by: Zhiyuan Cheng, et al.
Published: (2024-10-01)

Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review
by: Ammar Ahmed, et al.
Published: (2024-12-01)

Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists
by: Xiaolei Miao, et al.
Published: (2025-01-01)

Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action
by: Aleksandra Bykova, et al.
Published: (2024-10-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01)

Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
by: Sanbao Chai, et al.
Published: (2024-01-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Design, Structure–Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists
by: Jonathon R. Sawyer, et al.
Published: (2024-12-01)

The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
by: Mohammed Ali Gameil, et al.
Published: (2024-12-01)

Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia/reperfusion in rats
by: Rulin Mi, et al.
Published: (2024-12-01)